Development of ELISA Systems for Measurement of Human Tumor Necrosis Factor-Alpha (TNF-a)

The aim of this study was to develop a human tumor necrosis factor alpha (hTNF-a) ELISA system because specific and sensitive measurement of low levels of circulating TNF-a is very important for enlightening the immunopathologial mechanisms associated with TNF-a. Monoclonal antibodies 6A4c and 8A6 were produced against hTNF-a and were used as the capture antibody and the tracer antibody respectively for the first hTNF-a ELISA system (6A4c/biotin-8A6). Murine polyclonal IgG was used as the tracer antibody in the second hTNF-a ELISA system (6A4c/biotin-polyclonal IgG). Both systems could detect both recombinant hTNF-a and native hTNF-a. The detection limits defined as minimal concentration of hTNF-a were less than 4 pg/ml for the first and less than 12 pg/ml for the second ELISA systems. 6A4c/biotin-8A6 system resulted in some non-specific reactions to some extent with human sera; however, 6A4c/biotin-polyclonal IgG system produced acceptable background levels with human sera. A prominent inhibitory effect of TNF receptors-I and -II did not occur in any of the ELISA systems at physiological concentrations. Two different types of ELISA systems with high sensitivity and specificity were developed to measure hTNF-a level both in human serum and cell culture supernatant.

Anahtar Kelimeler:

TNF-a, ELISA

Development of ELISA Systems for Measurement of Human Tumor Necrosis Factor-Alpha (TNF-a)

Keywords:

TNF-a, ELISA,

PDF

___

Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti- TNFa inhibitor: implications for clinical use (review). Clin Immunol Immunopathol 81: 219-223, 1996.
Walsh CJ, Sugerman HJ, Mullen PG et al. Monoclonal antibody to tumor necrosis factor alpha attenuates cardiopulmonary dysfunction in porcine gram-negative sepsis. Arch Surg 127: 138- 145, 1992.
Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89: 9784-9788, 1992.
Neutrah M, Fuss I, Pasparakis M, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 27: 1743-1750, 1997.
Baker D, Butler D, Scallon BJ et al. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 24: 2040-2048, 1994.
Remick DG, Whiteside TL. Cytokine Assays. Cytokine Reference, Volume 1, (Eds-in-chief: Oppenheim JJ, Feldman M. Eds: Durum SK, Hirano T, Vilcek J, Nicola NA), Academic Press-A Hartcout Science and Technology Company, London, 2001, pp 53-81.
Mire-Sluis AR, Gaines-Das R, Thorpe R. Immunoassays for detecting cytokines: What are they really measuring? J Immunol Methods 186: 161-164, 1995.
Petrovas C, Daskas SM, Lianidou ES. Determination of TNF-αin serum by a highly sensitive enzyme amplified Lanthanide luminescence immunoassay. Clin Biochem 32: 241-247, 1999.
De Kossodo S, Houba V, Grau GE. WHO Collaborative study group. Assaying tumor necrosis factor concentrations in human serum. A WHO international collaborative study. J Immunol Methods 182: 107-114, 1995.
Meager A, Leung H, Wooley J. Assays for tumour necrosis factor and related cytokines. J Immunol Methods 116: 1-17, 1989.
Meager A, Parti S, Leung H et al. Preparation and characterization of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor (rTNF). Hybridoma 6: 305-311, 1987.
Corti A, Fassina G, Marcucci F et al. Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels. Biochem J 284: 905-910, 1992.
Petyovka N, Laych L, Voitenok NN. Homologous ELISA for detection of oligomeric human TNF: properties of the assay. J Immunol Methods 186: 161-170, 1995.
De Groote D, Grau G, Dehart I et al. Stabilization of functional tumor necrosis factor-alpha by its soluble TNF receptors. Eur Cytokine Netw 4: 359-62, 1993.
Madersbacher S, Berger P. Antibodies and immunoassays. Methods 21: 41-50, 2000.
Diamandis EP, Christopoulos TK. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem, 1991 625-636, 1991.
Kittigul L, Temprom W, Sujirarat D et al. Determinantion of tumor necrosis factor-alpha in dengue virus infected patients by sensitive biotin-streptavidin enzyme-linked immunosorbent assay. J Virol Methods 90: 51-57, 2000.
Hedeyati M, Yazdanparast R, Azizi F. Determination of human tumor necrosis factor-a by a highly sensitive enzyme immunoassay. Biochem Biophys Res Com. 289: 295-298, 2001.
Ameloot P, Fiers W, Burman WA et al. Characterization of the interaction between murine tumor necrosis factor and monoclonal antibodies. Cytokine 18: 158-163, 2002.
Thorpe R. Development of immunological standardization. J Immunol Methods 216: 93-101, 1998.
Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: Generation and biological functions. Biochem J 300: 281-290, 1994.
Hwu P, Schwarz S, Custer M, et al. Use of soluble recombinant TNF receptor to improve detection of TNF secretion in cultures of tumor infiltrating lymphocytes. J Immunol Methods 151: 139- 147, 1992.
Geigert J, Panschar BM, Taforo C et al. Parameters for the evaluation of long-term stability of tumor necrosis factor preparations. Dev Biol Standard 69: 129-138, 1988.
Ledur A, Fitting C, David B et al. Variable estimates of cytokine levels produced by commercial ELISA kits: Results using international cytokine standards. J Immunol Methods, 1995; 182: 171-179.